百花医药
(600721)
| 流通市值：50.41亿 | | | 总市值：50.41亿 |
| 流通股本：3.85亿 | | | 总股本：3.85亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 62,562,933.49 | 61,386,583.03 | 298,646,738.79 | 88,254,265.22 |
| 交易性金融资产 | 201,983,280.34 | 232,079,967.02 | - | 180,450,000 |
| 应收票据及应收账款 | 132,093,369.12 | 126,727,742.13 | 134,688,215.15 | 118,019,060.9 |
| 其中：应收票据 | 3,649,102.8 | 6,238,492.48 | 9,956,871.41 | 9,036,287.06 |
| 应收账款 | 128,444,266.32 | 120,489,249.65 | 124,731,343.74 | 108,982,773.84 |
| 应收款项融资 | 10,882,196.24 | 10,122,393.64 | 9,818,372.05 | 10,272,546.74 |
| 预付款项 | 5,027,791.91 | 6,418,085.64 | 2,199,213.76 | 4,053,504 |
| 其他应收款合计 | 3,195,106.93 | 2,978,219.41 | 2,002,848.35 | 4,312,133.59 |
| 存货 | 27,217,654.68 | 29,869,702.2 | 30,361,485.07 | 74,523,136.14 |
| 合同资产 | 76,872,898.14 | 82,292,692.44 | 84,558,291.31 | 95,999,205.22 |
| 其他流动资产 | 3,863,253.55 | 4,416,496.59 | 3,139,406.05 | 2,701,005.6 |
| 流动资产合计 | 523,698,484.4 | 556,291,882.1 | 565,414,570.53 | 578,584,857.41 |
| 非流动资产: | | | | |
| 长期股权投资 | 52,911,082.63 | 47,512,263.63 | 47,485,563.11 | 59,250,475.47 |
| 其他权益工具投资 | 3,901,629.01 | 3,901,629.01 | 3,901,629.01 | 7,661,309.55 |
| 其他非流动金融资产 | 9,370,796.95 | 6,593,591.83 | 3,762,681.7 | - |
| 投资性房地产 | 244,550,600 | 244,550,600 | 244,550,600 | 245,250,300 |
| 固定资产 | 135,545,153.61 | 134,511,143.2 | 138,267,713.85 | 140,697,878.9 |
| 无形资产 | 6,239,270.71 | 7,114,386.12 | 6,591,777.88 | 7,075,105.55 |
| 开发支出 | 35,681,372.09 | 34,459,261.58 | 34,414,137.35 | 36,681,402.28 |
| 商誉 | 11,485,077.64 | 11,485,077.64 | 11,485,077.64 | 11,485,077.64 |
| 长期待摊费用 | 2,201,437.15 | 2,468,787.94 | 2,720,090.09 | 2,251,442.42 |
| 递延所得税资产 | 34,682,883.94 | 35,073,836.24 | 34,838,606.93 | 31,107,654.94 |
| 其他非流动资产 | 4,866,302.73 | 9,244,307.86 | 4,137,885.63 | 599,897.16 |
| 非流动资产合计 | 541,435,606.46 | 536,914,885.05 | 532,155,763.19 | 542,060,543.91 |
| 资产总计 | 1,065,134,090.86 | 1,093,206,767.15 | 1,097,570,333.72 | 1,120,645,401.32 |
| 流动负债: | | | | |
| 短期借款 | - | 20,000,000 | - | - |
| 应付票据及应付账款 | 53,837,844.05 | 50,975,389.67 | 56,807,366.85 | 84,195,719.52 |
| 应付账款 | 53,837,844.05 | 50,975,389.67 | 56,807,366.85 | 84,195,719.52 |
| 预收款项 | 4,343,640.57 | 4,753,254.42 | 4,258,042.39 | - |
| 合同负债 | 97,606,326.74 | 101,413,400.99 | 110,133,566.63 | 124,348,586.08 |
| 应付职工薪酬 | 19,252,943.02 | 15,692,184.08 | 24,469,326.27 | 21,630,980.91 |
| 应交税费 | 2,385,065.02 | 4,037,373.11 | 4,236,837.14 | 4,101,147.41 |
| 其他应付款合计 | 33,991,998.91 | 33,702,601.13 | 40,429,902.02 | 34,499,641.68 |
| 应付股利 | 121,146.5 | 121,146.5 | 121,146.5 | 121,146.5 |
| 其他流动负债 | 3,651,549.82 | 4,886,682.09 | 6,508,558.38 | 9,133,034.01 |
| 流动负债合计 | 215,069,368.13 | 235,460,885.49 | 246,843,599.68 | 277,909,109.61 |
| 非流动负债: | | | | |
| 长期应付职工薪酬 | 876,918.72 | 959,642.54 | 962,800.66 | 1,132,375.37 |
| 预计负债 | 1,234,589.71 | 1,234,589.71 | 1,159,589.71 | 1,097,589.71 |
| 递延收益 | 775,665.25 | 1,036,976.87 | 1,298,288.45 | 1,569,400.03 |
| 递延所得税负债 | 46,516,211.72 | 46,033,919.46 | 45,468,026.7 | 45,116,277.24 |
| 非流动负债合计 | 49,403,385.4 | 49,265,128.58 | 48,888,705.52 | 48,915,642.35 |
| 负债合计 | 264,472,753.53 | 284,726,014.07 | 295,732,305.2 | 326,824,751.96 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 384,547,635 | 384,547,635 | 384,547,635 | 384,547,635 |
| 资本公积 | 361,781,696.5 | 362,336,754.75 | 362,336,754.75 | 2,267,881,103.37 |
| 其他综合收益 | 7,235,465.6 | 7,235,465.6 | 7,235,465.6 | 7,195,146.14 |
| 盈余公积 | 3,495,545.65 | 3,495,545.65 | 3,495,545.65 | 5,030,274.41 |
| 未分配利润 | 43,600,994.58 | 50,865,352.08 | 44,222,627.52 | -1,870,833,509.56 |
| 归属于母公司股东权益合计 | 800,661,337.33 | 808,480,753.08 | 801,838,028.52 | 793,820,649.36 |
| 股东权益合计 | 800,661,337.33 | 808,480,753.08 | 801,838,028.52 | 793,820,649.36 |
| 负债和股东权益合计 | 1,065,134,090.86 | 1,093,206,767.15 | 1,097,570,333.72 | 1,120,645,401.32 |
| 公告日期 | 2026-08-25 | 2026-04-25 | 2026-03-28 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |